Rivaroxaban(Xarelto,BAY 59-7939)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-valvular Atrial Fibrillation (NVAF)
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Trial Timeline
Dec 3, 2018 → Dec 15, 2021
NCT ID
NCT03746301About Rivaroxaban(Xarelto,BAY 59-7939)
Rivaroxaban(Xarelto,BAY 59-7939) is a pre-clinical stage product being developed by Bayer for Non-valvular Atrial Fibrillation (NVAF). The current trial status is completed. This product is registered under clinical trial identifier NCT03746301. Target conditions include Non-valvular Atrial Fibrillation (NVAF).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03746301 | Pre-clinical | Completed |
Competing Products
17 competing products in Non-valvular Atrial Fibrillation (NVAF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| DU-176b 15mg + DU-176b 30mg + DU-176b 60mg | Daiichi Sankyo | Phase 3 | 77 |
| Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin | Daiichi Sankyo | Approved | 85 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| AZD0837 + Aspirin | AstraZeneca | Phase 2 | 52 |
| Apixaban + Warfarin | Pfizer | Pre-clinical | 22 |
| Warfarin + Apixaban | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Approved | 84 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto,Bay 59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Warfarin | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY-597939) + VKAs | Bayer | Pre-clinical | 20 |
| Non-VKA Oral Anticoagulants (NOAC) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto_ BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) | Bayer | Pre-clinical | 20 |